TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00304018

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Zopiclone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Zopiclone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Zopiclone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Zopiclone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Zopiclone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Zopiclone
Study: NCT00304018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Zopiclone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Zopiclone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Zopiclone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Zopiclone
Study: NCT00304018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation
Study: NCT04061954

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive family intervention including individual sessions of FORNET
Description: Families in the intervention group received:~1. Parents participate in a group intervention once a week for about 20 weeks, including psychoeducation on mental health and drug and alcohol abuse, anger management, family planning, parenting skills, communication skills, and dealing with couples conflicts~2. Family visits to address topics as family cohesion, intra-familial communication and psychological basic need of children~3. Trauma-focused therapies (FORNET), which aim also at reducing violent behaviour~4. Parents receive training regarding agriculture and micro credit projects, and financial assistance~5. One child per family receives a social skill training group preparing them for returning to school~6. Access to schools and school material~7. If needed medical assistance is provided~8. If needed legal assistance is provided
Study: NCT01943838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR245408
Description: Pharmaceutical form: tablet Route of administration: oral
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Zopiclone
Study: NCT01409083

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: intravenous sodium bicarbonate
Description: Dilted sodium bicarbonate 2.1%

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intravenous sodium bicarbonate
Description: Dilted sodium bicarbonate 2.1%
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Zopiclone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Zopiclone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Zopiclone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Zopiclone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Zopiclone

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Jelly with Zopiclone

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Jelly with Zopiclone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Zopiclone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Zopiclone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Zopiclone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Zopiclone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Zopiclone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Alprazolam
Study: NCT04200456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab
Description: Study participants receive rozanolixizumab by subcutaneous infusion at pre-specified time points.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study participants receive placebo by subcutaneous infusion at pre-specified time points.
Study: NCT02614950

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment interruption
Study: NCT04225728

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Sucrose IV
Description: Intervention will consisted of the administration for the IV route.~-The IV route in two doses will be diluted bolus injection of iron or normal saline at day 0 and day 14.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric polymaltose hydroxide complex IM
Description: Intervention will consisted of the administration for the IM route. Drug will be given in two series of injection; the first series will began at day 0 and consist of administration of 300 mg of iron per day in intramuscular injection up to the half of the total dose and the second series will began at day 14 for the administration of the other half with the same scheme than the first.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: 100 ml i.v. of normal saline administered at Day 0 and at day 14.
Study: NCT04458233

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: long axis FNA method
Description: ). A long-axis view (i.e., a longitudinal image of the needle) is obtained by placing the US probe in a parallel position relative to the course of the needle. Short-axis and long-axis views can be used for both US assistance and guidance of FNA procedure. Correspondingly, approaching the nodule with the needle from the lateral or frontal aspect results in either a long axis or short axis view of the needle on the US screen

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: long axis FNA method
Description: ). A long-axis view (i.e., a longitudinal image of the needle) is obtained by placing the US probe in a parallel position relative to the course of the needle. Short-axis and long-axis views can be used for both US assistance and guidance of FNA procedure. Correspondingly, approaching the nodule with the needle from the lateral or frontal aspect results in either a long axis or short axis view of the needle on the US screen
Study: NCT01650233

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mindfulness-based stress reduction

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction
Study: NCT01590238

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRFM treatment
Description: Study participants are treated in the initial visit, and at the 1 and 2 month follow-up visit. 4-8 cc of autologous platelet rich fibrin matrix (PRFM) is isolated from 9-18 cc of peripheral blood. PRFM is then injected intradermally in 0.10 cc aliquots in areas of alopecia for each treatment.
Study: NCT02904473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GROWell
Description: The GROWell intervention is a mobile health technology, including diet tracking, skills training and tailored feedback based on digital and human support strategies. Its message content is geared toward healthy diet change during pregnancy.
Study: NCT02684266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: SHR6390 either 25, 50mg, 75mg, 100mg, 125mg, 150mg, 175mg given orally, QD
Study: NCT06020365

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sequential fecal microbiota transplant combined with small intestinal fluid transplant
Description: for eligible patients, the investigator use rifaximin, three times daily, 0.4 g each time, lasting 6 days followed by fecal microbiota transplant combined with small intestinal fluid transplant for 6 days. These procedures were repeated every 28 days.
Study: NCT02384707

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: allegic food
Description: Reintroduction procedure for small doses :~* Administration of the first dose~* Clinical monitoring for 45 minutes~* Administration of the second dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00853125

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes
Description: Patients with a partially HLA-matched family member who can serve as a hematopoietic stem cell transplant donor will receive partially HLA-matched irradiated donor lymphocytes approximately every 8 weeks depending upon response

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Sunitinib will be administered orally at a dose of 50 mg qd for 4 consecutive weeks followed by 2 weeks off for every cycle.
Study: NCT03719404

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sodium hypochlorite
Description: sodium hypochlorite is used as primary irrigant and edta is used as secondary irrigant in endodontic retreatment cases
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Alprazolam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Alprazolam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Alprazolam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Alprazolam
Study: NCT01958385

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Diet and Exercise
Description: A structured diet and exercise plan
Study: NCT03719404

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: chlorhexidine
Description: Chlorhexidine is used as primary irrigant and citric acid is used as secondary irrigant in endodontic retreatment cases
Study: NCT02599649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lirilumab
Description: 3 mg/kg by vein every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lirilumab
Description: 3 mg/kg by vein every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lirilumab
Description: 3 mg/kg by vein every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lirilumab
Description: 3 mg/kg by vein every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3 mg/kg by vein on Days 7 and 21 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3 mg/kg by vein on Days 7 and 21 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75 mg/m\^2 by vein for 7 days of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75 mg/m\^2 by vein for 7 days of a 28 day cycle.
Study: NCT02408081

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Focused Nursing
Description: All patients receive treatment as usual. Additionally, patients in the intervention arm receives family focused nursing consultations which are structured as sessions focusing on change, improvement and/or maintenance of family function within cognitive, affective and behavioral knowledge. Each session is organized and individualized according to the wishes and needs for education and counseling of the families within a period of one months.
Study: NCT02498067

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: rPlan dual protection waiting room app intervention
Study: NCT00780637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bradykinin
Description: Patients receive 0, 10, 20, and 40 ng/100cc forearm volume/min of bradykinin intrabrachial.
Study: NCT02185157

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dual -task exercises
Description: physical exercises sections with gait and a second task like talk answering some questions or making some exercise with the arms.
Study: NCT04034173

Intervention type: DRUG
Group type: OTHER
Intervention: Panitumumab
Description: Panitumumab 6 mg/kg BW as 60-min i.v. infusion\* D1~\*If the 1st infusion is well tolerated, all subsequent infusions can be applied over 30-60 minutes.

Intervention type: DRUG
Group type: OTHER
Intervention: Panitumumab
Description: Panitumumab 6 mg/kg BW as 60-min i.v. infusion\* D1~\*If the 1st infusion is well tolerated, all subsequent infusions can be applied over 30-60 minutes.
Study: NCT02185157

Intervention type: OTHER
Group type: OTHER
Intervention: Aerobic training
Description: The same doses of aerobic training, i.e., 50 minutes, was delivered in groups of five participants. Each session will include 10 minutes of warm-up, 30 minutes of aerobic training on an ergometric bicycle at 60 to 80% of the participants' maximum heart rates,and 10 minutes of cool-down exercises.
Study: NCT04034173

Intervention type: DRUG
Group type: OTHER
Intervention: Panitumumab
Description: Panitumumab 6 mg/kg BW as 60-min i.v. infusion\* D1~\*If the 1st infusion is well tolerated, all subsequent infusions can be applied over 30-60 minutes.

Intervention type: DRUG
Group type: OTHER
Intervention: Irinotecan
Description: Irinotecan 180 mg/m² BSA i.v., 30 - 90 min D1

Intervention type: DRUG
Group type: OTHER
Intervention: Irinotecan
Description: Irinotecan 180 mg/m² BSA i.v., 30 - 90 min D1

Intervention type: DRUG
Group type: OTHER
Intervention: Irinotecan
Description: Irinotecan 180 mg/m² BSA i.v., 30 - 90 min D1

Intervention type: DRUG
Group type: OTHER
Intervention: Folinic acid
Description: Folinic acid (racemic) 400 mg/m²BSA i.v., 120 min D1

Intervention type: DRUG
Group type: OTHER
Intervention: Folinic acid
Description: Folinic acid (racemic) 400 mg/m²BSA i.v., 120 min D1

Intervention type: DRUG
Group type: OTHER
Intervention: Folinic acid
Description: Folinic acid (racemic) 400 mg/m²BSA i.v., 120 min D1

Intervention type: DRUG
Group type: OTHER
Intervention: 5-FU
Description: 5-FU 400 mg/m² BSA, bolus, D1 5-FU 2400 mg/m² BSA i.v. infusion over a period of 46 h D1-2

Intervention type: DRUG
Group type: OTHER
Intervention: 5-FU
Description: 5-FU 400 mg/m² BSA, bolus, D1 5-FU 2400 mg/m² BSA i.v. infusion over a period of 46 h D1-2

Intervention type: DRUG
Group type: OTHER
Intervention: 5-FU
Description: 5-FU 400 mg/m² BSA, bolus, D1 5-FU 2400 mg/m² BSA i.v. infusion over a period of 46 h D1-2
Study: NCT05683054

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dose tapering of adalimumab in patients with supratheurapeutic serum trough levels
Description: In the dose tapering arm, adalimumab dosing frequency will be lowered to 40 mg every 3 weeks in patients who have supratherapeutic serum trough levels of adalimumab (33% reduction). If patients still have a good clinical response and supratherapeutic adalimumab serum trough levels, will be further tapered to a dose regimen of 1 subcutaneous injection (40mg) every 4 weeks (50% dose reduction).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Venapuncture
Description: Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of adalimumab

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Venapuncture
Description: Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of adalimumab

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dermatology Life Quality Index (DLQI)
Description: The impact of the disease on the patient will be assessed using the dermatology life quality index (DLQI).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dermatology Life Quality Index (DLQI)
Description: The impact of the disease on the patient will be assessed using the dermatology life quality index (DLQI).
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Alprazolam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Alprazolam
Study: NCT05683054

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EQ-5D-5L questionnaire
Description: The EQ-5D-5L which is a standardized instrument developed by the EuroQol Group as a measure of health-related quality of life that can be used in a wide range of health conditions and treatments will be assessed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EQ-5D-5L questionnaire
Description: The EQ-5D-5L which is a standardized instrument developed by the EuroQol Group as a measure of health-related quality of life that can be used in a wide range of health conditions and treatments will be assessed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dried blood spot sampling
Description: A subset of patients will sample additionally by using dried blood sampling after the first drug injection post-inclusion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dried blood spot sampling
Description: A subset of patients will sample additionally by using dried blood sampling after the first drug injection post-inclusion.
Study: NCT00755287

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: starting dose 10 IU daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: As prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: As prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: As prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taspoglutide
Description: 10 mg once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taspoglutide
Description: 20 mg once weekly (after 4 weeks of taspoglutide 10 mg once weekly)
Study: NCT03744923

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transmuscular QL block
Description: Ultrasound device will be used; The probe is placed in the mid-axillary line cranially to the iliac crest to identify the three muscles of the anterior abdominal wall. Then, scan dorsally keeping the transverse orientation until observing that the transversusabdominus muscle becomes aponeurotic, and this aponeurosis is followed until the QL muscle is clearly visualized with its attachment to the lateral edge of the transverse process of the L2 vertebral body and visualize the thoracolumbar fascia at the lateral edge of the QL muscle.~The view of the psoas major muscle (PM) anteriorly, the erector spinae muscle (ESM) posteriorly and the QL muscle adherent to the apex of the transverse process result in a well recognizable pattern of a Shamrock with three leaves (trifoliate).
Study: NCT01958385

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet and Exercise
Description: A structured diet and exercise plan
Study: NCT02736188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceneuramic Acid Extended-Release Tablets
Study: NCT03744923

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus Abdominus Plane block
Description: Posterior TAP block will be performed on the same side of surgery (unilateral) under ultrasonographic guidance with a with broadband (7-13MHz) linear probe covered with a sterile plastic sheath. Probe will positioned transversely midway between the iliac crest and the costal margin at level of mid axillary line.~Once the external oblique muscle (EOM), internal oblique muscle (IOM) and transversus abdominis muscle (TAM) are visualized at the level of the mid axillary line between the 12th rib and the iliac crest, the puncture area and the ultrasound probe were prepared in a sterile manner. After identification of the neuro-facial plane between IOM and TAM, block was performed with 20G spinal needle. The needle will be directed to approach the TAP with in-plane USG-guided technique. Once the tip of the needle placed in the space between the IOM and TAM, Inject a 1 ml test dose of lidocaine 2% for hydrovisualization of needle-tip position and confirming its correct postioning.
Study: NCT04358575

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Triathlon CS Knee System with all-polyethylene tibial components
Description: Primary Total Knee Replacement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triathlon CS Knee System with metal-backed modular components
Description: Primary Total Knee Replacement
Study: NCT00403793

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etonogestrel with testosterone undecanoate
Description: 42 or 44 weeks with etonogestrel implant and testosterone undecanoate injections every 10 to 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 42 or 44 weeks with placebo implant and placebo injections
Study: NCT02010554

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Education
Description: Give patients a pamphlet discussing pros and cons of disease modifying therapies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Education
Description: Give patients a pamphlet discussing pros and cons of disease modifying therapies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing-Cognitive Behavioral Therapy
Description: A telephone based talk therapy discussing pros and cons of medication use in MS.
Study: NCT00452010

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CEFAR PRIMO TENS Class IIA (active)
Description: Active TENS. 4 sessions per day during 3 months.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CEFAR PRIMO TENS Class IIA (no active)
Description: Placebo TENS. 4 sessions per day during 3 months.
Study: NCT03487029

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short duration
Description: exercise Short duration high intensity training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long duration
Description: exercise Long duration high intensity training
Study: NCT02107482

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Levia Narrow Band UVB
Description: The device's spectral output is is Narrow Band UVB (NB-UVB) (NB-Levia): 308-312 nm

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Levia sham/visible-light source
Description: the light spectrum is in the range of 400-700nm, the light is produced using the same Levia® device. Levia® enable the user to switch off the UVB light and only produce visible light spectrum.
Study: NCT02747537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study: NCT01953120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: Subjects will receive intravenous belatacept at 5mg/kg every other week starting from day 1 and continuing with weeks 2, 4, 6, and 8, and then monthly at months 3, 4, 5, and 6. At month 6 patients may elect to continue for an additional six-month period of belatacept administration.